Cited by 555Computational Drug Discovery MethodsProtein Degradation and InhibitorsHeterocyclic Compound Synthesis and Bioactivity

The DOI matches its Crossref record; 251 of the 251 references it cites were found in a registry or an index.

Polypharmacology by Design: A Medicinal Chemist’s Perspective on Multitargeting Compounds

Proschak, Ewgenij, Stark, Holger, Merk, Daniel·2019·Journal of Medicinal Chemistry

DOI 10.1021/acs.jmedchem.8b00760

Open this paper in CoChat — free account

Abstract

Multitargeting compounds comprising activity on more than a single biological target have gained remarkable relevance in drug discovery owing to the complexity of multifactorial diseases such as cancer, inflammation, or the metabolic syndrome. Polypharmacological drug profiles can produce additive or synergistic effects while reducing side effects and significantly contribute to the high therapeutic success of indispensable drugs such as aspirin. While their identification has long been the result of serendipity, medicinal chemistry now tends to design polypharmacology. Modern in vitro pharmacological methods and chemical probes allow a systematic search for rational target combinations and recent innovations in computational technologies, crystallography, or fragment-based design equip multitarget compound development with valuable tools. In this Perspective, we analyze the relevance of multiple ligands in drug discovery and the versatile toolbox to design polypharmacology. We conclude that despite some characteristic challenges remaining unresolved, designed polypharmacology holds enormous potential to secure future therapeutic innovation.

Integrity signals

Registry

Crossref · 10.1021/acs.jmedchem.8b00760

Cites

251 of 251 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,484
Extended-Connectivity Fingerprints
Rogers, D. O. W., & Hahn, M. (2010) · Journal of Chemical Information and Modeling · doi:10.1021/ci100050t · Cited by 7,925
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
Network pharmacology: the next paradigm in drug discovery
Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622
Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay
Molina, D. M., Jafari, R., Ignatushchenko, M., Seki, T., Larsson, E. A., Dan, C., Sreekumar, L., Cao, Y., & Nordlund, P. (2013) · Science · doi:10.1126/science.1233606 · Cited by 2,261
LigandScout: 3-D Pharmacophores Derived from Protein-Bound Ligands and Their Use as Virtual Screening Filters
Wolber, G., & Langer, T. (2004) · Journal of Chemical Information and Modeling · doi:10.1021/ci049885e · Cited by 1,989
The ChEMBL bioactivity database: an update
Bento, A. P., Gaulton, A., Hersey, A., Bellis, L. J., Chambers, J. K., Davies, M., Krüger, F. A., Light, Y., Mak, L., McGlinchey, S., et al. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt1031 · Cited by 1,520
Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4309 · Cited by 1,344
Concepts and applications of molecular similarity
Johnson, M. A., & Maggiora, G. M. (1990) · Wiley eBooks · Cited by 1,301

Show all 251 references

Research works printed but not linked: 1

Glen R. C., 2006, IDrugs, 9, 199

Sorted by citations

Items 101–200 of 555

Drug Development for Alzheimer’s and Parkinson’s Disease: Where Do We Go Now?
Sequeira, L., Benfeito, S., Fernandes, C., Gaspar, A., Lima, I., Peixoto, J., Alves, C., Machado, C. S., Borges, F., & Chavarria, D. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16060708 · Cited by 37
In Search for Multi-Target Ligands as Potential Agents for Diabetes Mellitus and Its Complications—A Structure-Activity Relationship Study on Inhibitors of Aldose Reductase and Protein Tyrosine Phosphatase 1B
Ottanà, R., Paoli, P., Cappiello, M., Nguyen, T. N., Adornato, I., CORSO, A. D., Genovese, M., Nesi, I., Moschini, R., Naß, A., et al. (2021) · Molecules · doi:10.3390/molecules26020330 · Cited by 36
Role of Artificial Intelligence in Drug Discovery and Target Identification in Cancer
Sharma, V., Singh, A. K., Chauhan, S., Sharma, P. K., Chaudhary, S., Sharma, A., Porwal, O., & Fuloria, N. K. (2023) · Current Drug Delivery · doi:10.2174/1567201821666230905090621 · Cited by 36
Dual Inhibitors of AChE and BACE-1 for Reducing Aβ in Alzheimer’s Disease: From In Silico to In Vivo
Stern, N., Gacs, A., Tátrai, E., Flachner, B., Hajdú, I., Dobi, K., Bágyi, I., Dormán, G., Lőrincz, Z., Cseh, S., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113098 · Cited by 35
The Advent of Molecular Targeted Therapies Against Cancer. Toward Multi‐Targeting Drugs Through Materials Engineering: A Possible Future Scenario
Puzzo, M., Santo, M. D., Morelli, C., Leggio, A., & Pasqua, L. (2024) · Small Science · doi:10.1002/smsc.202400113 · Cited by 37
Multitarget Anticancer Agents Based on Histone Deacetylase and Protein Kinase CK2 Inhibitors
Martínez, R., Geronimo, B. D., Pastor, M., Zapico, J. M., Coderch, C., Panchuk, R. R., Skorokhyd, N. R., Masłyk, M., Ramos, A., & de Pascual‐Teresa, B. (2020) · Molecules · doi:10.3390/molecules25071497 · Cited by 35
Carbon Monoxide Inhibits Cytochrome P450 Enzymes CYP3A4/2C8 in Human Breast Cancer Cells, Increasing Sensitivity to Paclitaxel
Kawahara, B., Faull, K. F., Janzen, C., & Mascharak, P. K. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00404 · Cited by 35
Design and structural optimization of dual FXR/PPARδ activators
Schierle, S., Neumann, S., Heitel, P., Willems, S., Kaiser, A., Pollinger, J., & Merk, D. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00618 · Cited by 34
Self-citation
Optimized Opioid-Neurotensin Multitarget Peptides: From Design to Structure–Activity Relationship Studies
González, S., Dumitrascuta, M., Eiselt, E., Louis, S., Kunze, L., Blasiol, A., Vivancos, M., Previti, S., Dewolf, E., Martin, C., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01376 · Cited by 34
Molecular Modeling of Histamine Receptors—Recent Advances in Drug Discovery
Mehta, P., Miszta, P., & Filipek, S. (2021) · Molecules · doi:10.3390/molecules26061778 · Cited by 34
Multitarget-Directed Ligands for Alzheimer’s Disease: Recent Novel MTDLs and Mechanistic Insights
Almaghrabi, M. (2025) · Pharmaceuticals · doi:10.3390/ph18111685 · Cited by 33
Antimicrobial peptides: A novel and promising arsenal against methicillin-resistant Staphylococcus aureus (MRSA) infections
Odunitan, T. T., Oyaronbi, A. O., Adebayo, F. A., Adekoyeni, P. A., Apanisile, B. T., Oladunni, T. D., & Saibu, O. A. (2023) · Pharmaceutical Science Advances · doi:10.1016/j.pscia.2023.100034 · Cited by 32
Exploring Structure-Activity Relationship in Tacrine-Squaramide Derivatives as Potent Cholinesterase Inhibitors
Svobodová, B., Mezeiová, E., Hepnarová, V., Hrabinová, M., Múčková, Ľ., Kobrlová, T., Jun, D., Soukup, O., Jimeno, M. L., Marco, J. L., et al. (2019) · Biomolecules · doi:10.3390/biom9080379 · Cited by 32
Design, synthesis and biological evaluation of new series of hexahydroquinoline and fused quinoline derivatives as potent inhibitors of wild-type EGFR and mutant EGFR (L858R and T790M)
Shaheen, M. A., El-Emam, A. A.-R., & El‐Gohary, N. S. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104274 · Cited by 32
Medicinal polypharmacology: Exploration and exploitation of the polypharmacolome in modern drug development
Stefan, S. M., & Rafehi, M. (2023) · Drug Development Research · doi:10.1002/ddr.22125 · Cited by 32
Rational design of new multitarget histamine H3 receptor ligands as potential candidates for treatment of Alzheimer’s disease
Łażewska, D., Bajda, M., Kaleta, M., Zaręba, P., Doroż-Płonka, A., Siwek, A., Alachkar, A., Mogilski, S., Saad, A. K., Kuder, K., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112743 · Cited by 31
Dual-Acting Small Molecules: Subtype-Selective Cannabinoid Receptor 2 Agonist/Butyrylcholinesterase Inhibitor Hybrids Show Neuroprotection in an Alzheimer’s Disease Mouse Model
Spatz, P., Steinmüller, S. A. M., Tutov, A., Poeta, E., Morilleau, A., Carles, A., Deventer, M. H., Hofmann, J., Stove, C. P., Monti, B., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00541 · Cited by 31
Binding site characterization – similarity, promiscuity, and druggability
Ehrt, C., Brinkjost, T., & Koch, O. (2019) · MedChemComm · doi:10.1039/c9md00102f · Cited by 31
Experimental and Computational Approaches to Improve Binding Affinity in Chemical Biology and Drug Discovery
Nayarisseri, A. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/156802662019200701164759 · Cited by 31
Second-Generation Dual FXR/sEH Modulators with Optimized Pharmacokinetics
Helmstädter, M., Kaiser, A., Brunst, S., Schmidt, J., Ronchetti, R., Weizel, L., Proschak, E., & Merk, D. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00831 · Cited by 30
Self-citation
Recent advances in EZH2-based dual inhibitors in the treatment of cancers
Yang, X., Lu, X., & Li, Y. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115461 · Cited by 30
A dual farnesoid X receptor/soluble epoxide hydrolase modulator treats non-alcoholic steatohepatitis in mice
Khan, A. H., Schmidt, J., Stavniichuk, A., Imig, J. D., & Merk, D. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.05.023 · Cited by 30
Self-citation
Exploring acetaminophen prodrugs and hybrids: a review
Kouznetsov, V. V. (2024) · RSC Advances · doi:10.1039/d4ra00365a · Cited by 29
Anti-Tuberculosis Mur Inhibitors: Structural Insights and the Way Ahead for Development of Novel Agents
Mehta, K., Khambete, M., Abhyankar, A. N., & Omri, A. (2023) · Pharmaceuticals · doi:10.3390/ph16030377 · Cited by 29
Ugi Reaction Synthesis of Oxindole–Lactam Hybrids as Selective Butyrylcholinesterase Inhibitors
Brandão, P., López, Ó., Leitzbach, L., Stark, H., Fernández‐Bolaños, J. G., Burke, A. J., & Piñeiro, M. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00344 · Cited by 28
Self-citation
Structure-Based Design and Optimization of FPPQ, a Dual-Acting 5-HT3 and 5-HT6 Receptor Antagonist with Antipsychotic and Procognitive Properties
Zajdel, P., Grychowska, K., Mogilski, S., Kurczab, R., Satała, G., Bugno, R., Kos, T., Gołębiowska, J., Malikowska‐Racia, N., Nikiforuk, A., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00224 · Cited by 28
Cashew Nut Shell Liquid (CNSL) as a Source of Drugs for Alzheimer’s Disease
Uliassi, E., de Oliveira, A. S., Nascente, L. D. C., Romeiro, L. A. S., & Bolognesi, M. L. (2021) · Molecules · doi:10.3390/molecules26185441 · Cited by 28
Dual HDAC/BRD4 Inhibitors Relieves Neuropathic Pain by Attenuating Inflammatory Response in Microglia After Spared Nerve Injury
Borgonetti, V., Meacci, E., Pierucci, F., Romanelli, M. N., & Galeotti, N. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01243-6 · Cited by 27
Discovery of a 2,6-diarylpyridine-based hydroxamic acid derivative as novel histone deacetylase 8 and tubulin dual inhibitor for the treatment of neuroblastoma
Tang, H., Liang, Y., Shen, H., Cai, S., Yu, M., Fan, H., Ding, K., & Wang, Y. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.106112 · Cited by 27
Appendix A. dithioloquinolinethiones as new potential multitargeted antibacterial and antifungal agents: Synthesis, biological evaluation and molecular docking studies
Карцев, В. Г., Shikhaliev, K. S., Geronikaki, A. A., Medvedeva, S. M., Ledenyova, I. V., Krysin, M. Y., Petrou, A., Ćirić, A., Glamočlija, J., & Sokóvić, M. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.04.046 · Cited by 27
The Emerging Role of COX-2, 15-LOX and PPARγ in Metabolic Diseases and Cancer: An Introduction to Novel Multi-target Directed Ligands (MTDLs)
Alaaeddine, R. A., Elzahhar, P. A., AlZaim, I., Abou-Kheir, W. G., Belal, A. S. F., & EL‐Yazbi, A. F. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327999200820173853 · Cited by 26
Advances in SHP2 tunnel allosteric inhibitors and bifunctional molecules
Guo, Z., Duan, Y., Sun, K., Zheng, T., Liu, J., Xu, S., & Xu, J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116579 · Cited by 26
Dual inhibition of CB1 receptors and iNOS, as a potential novel approach to the pharmacological management of acute and long COVID‐19
Çınar, R., Iyer, M. R., & Kunos, G. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15461 · Cited by 26
Explainable machine learning predictions of dual-target compounds reveal characteristic structural features
Feldmann, C., Philipps, M., & Bajorath, J. (2021) · Scientific Reports · doi:10.1038/s41598-021-01099-4 · Cited by 26
Structure‐Guided Design of G‐Protein‐Coupled Receptor Polypharmacology
Kampen, S., Vo, D. D., Zhang, X., Panel, N., Yang, Y., Jaiteh, M., Matricon, P. G., Svenningsson, P., Brea, J. M., Loza, M. I., et al. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202101478 · Cited by 25
Further exploration of the structure-activity relationship of dual soluble epoxide hydrolase/fatty acid amide hydrolase inhibitors
Wilt, S., Kodani, S. D., Valencia, L., Hudson, P. K., Sanchez, S., Quintana, T., Morisseau, C. H. P., Hammock, B. D., Kandasamy, R., & Pecic, S. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116507 · Cited by 25
Multi-target-based polypharmacology prediction (mTPP): An approach using virtual screening and machine learning for multi-target drug discovery
Liu, K., Chen, X., Ren, Y., Liu, C., Lv, T., Liu, Y., & Zhang, Y. (2022) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2022.110239 · Cited by 25
Recent development of multi-targeted inhibitors of human topoisomerase II enzyme as potent cancer therapeutics
Singh, V. K., Afshan, T., Tyagi, P. K., Varadwaj, P. K., & Sahoo, A. K. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.12.013 · Cited by 25
Dual Piperidine-Based Histamine H 3 and Sigma-1 Receptor Ligands in the Treatment of Nociceptive and Neuropathic Pain
Szczepańska, K., Karcz, T. P., Dichiara, M., Mogilski, S., Kalinowska‐Tłuścik, J., Pilarski, B., Leniak, A., Pietruś, W., Podlewska, S., Popiołek-Barczyk, K., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00430 · Cited by 25
Self-citation
Small molecule inhibitors targeting heat shock protein 90: An updated review
Li, Y., Dong, J., & Qin, J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116562 · Cited by 25
Identification of Target Associations for Polypharmacology from Analysis of Crystallographic Ligands of the Protein Data Bank
Pinzi, L., & Rastelli, G. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00821 · Cited by 25
Medicinal polypharmacology—a scientific glossary of terminology and concepts
Stefan, S. M., & Rafehi, M. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1419110 · Cited by 24
EGFR and COX-2 Dual Inhibitor: The Design, Synthesis, and Biological Evaluation of Novel Chalcones
Musa, A., Mostafa, E. M., Bukhari, S. N. A., Alotaibi, N. H., El-Ghorab, A. H., Farouk, A., Nayl, A. A., Ghoneim, M. M., & Abdelgawad, M. A. (2022) · Molecules · doi:10.3390/molecules27041158 · Cited by 24
Development and In Vitro and In Vivo Evaluation of an Antineoplastic Copper(II) Compound (Casiopeina III-ia) Loaded in Nonionic Vesicles Using Quality by Design
Aguilar-Jiménez, Z., González-Ballesteros, M. M., Davila-Manzanilla, S., Espinoza-Guillén, A., & Ruíz-Azuara, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112756 · Cited by 24
Target- and prodrug-based design for fungal diseases and cancer-associated fungal infections
Liu, N., Tu, J., Huang, Y., Yang, W., Wang, Q., Li, Z., & Sheng, C. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114819 · Cited by 24
Discovery of 4-(N-dithiobenzyl piperazine)-1,8-naphthalimide as a potent multi-target antitumor agent with good efficacy, limited toxicity, and low resistance
Liang, S., Liang, G.-B., Wang, H., Jiang, H., Ma, X., Wei, J.-H., Huang, R.-Z., & Zhang, Y. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115937 · Cited by 24
Synthetic Routes to Quinoline-Based Derivatives having Potential Anti-Bacterial and Anti-Fungal Properties
Sharma, S., & Singh, S. (2022) · Current Organic Chemistry · doi:10.2174/1385272827666221021140934 · Cited by 23
Research progress of STAT3-based dual inhibitors for cancer therapy
Yang, X.-J., Xu, L., Yang, L., & Xu, S. (2023) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2023.117382 · Cited by 23
Design, synthesis and biological evaluation of novel c-Met/HDAC dual inhibitors
Dong, Y., Hu, H., Sun, Y., Qin, M., Gong, P., Hou, Y., & Zhao, Y. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127610 · Cited by 22
Benzimidazole-based dual dipeptidyl peptidase-4 and xanthine oxidase inhibitors
Tomović, K., Ilić, B. S., Šmelcerović, Ž., Miljković, M., Yancheva, D. Y., Kojić, M., Mavrova, A. T., Kocic, G. M., & Šmelcerović, A. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.108873 · Cited by 22
Insight into potent leads for alzheimer's disease by using several artificial intelligence algorithms
He, X., Zhao, L., Zhong, W., Chen, H., Shan, X., Tang, N., & Chen, C. Y. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110360 · Cited by 22
Structure-activity relationships of dually-acting acetylcholinesterase inhibitors derived from tacrine on N-methyl-d-Aspartate receptors
Górecki, L., Misiachna, A., Damborský, J., Doležal, R., Korábečný, J., Cejkova, L., Hakenova, K., Chvojková, M., Karasová, J. Ž., Prchal, L., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113434 · Cited by 22
Evolution of kinase polypharmacology across HSP90 drug discovery
Antolín, A. A., Clarke, P. A., Collins, I., Workman, P., & Al‐Lazikani, B. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.05.004 · Cited by 22
Synthesis of novel pyrazino[1,2-a]indol-1(2H)-one derivatives as potent cholinesterase inhibitors and their in vitro and in silico evaluations
Kuzu, B., & Demir, Y. (2025) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2025.110504 · Cited by 21
Discovery of benzamide-based PI3K/HDAC dual inhibitors with marked pro-apoptosis activity in lymphoma cells
Deng, J., Hou, B., Hou, X., Chen, Y., Zhang, T., Chen, H., Wang, Y., & Li, X. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115915 · Cited by 21
Histamine H3 receptor antagonist E177 attenuates amnesia induced by dizocilpine without modulation of anxiety-like behaviors in rats
Alachkar, A., Khan, N., Łażewska, D., Kieć‐Kononowicz, K., & Sadek, B. S. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s193125 · Cited by 21
Evaluation of the published kinase inhibitor set to identify multiple inhibitors of bacterial ATP-dependent mur ligases
Hrast, M., Rožman, K., Ogris, I., Škedelj, V., Patin, D., Sova, M., Barreteau, H., Gobec, S., Grdadolnik, S. G., & Zega, A. (2019) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2019.1608981 · Cited by 21
Dual Target Ligands with 4-tert-Butylphenoxy Scaffold as Histamine H3 Receptor Antagonists and Monoamine Oxidase B Inhibitors
Łażewska, D., Olejarz‐Maciej, A., Reiner‐Link, D., Kaleta, M., Latacz, G., Zygmunt, M., Doroż-Płonka, A., Karcz, T. P., Frank, A., Stark, H., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103411 · Cited by 21
Self-citation
Exploitation of dihydroorotate dehydrogenase (DHODH) and p53 activation as therapeutic targets: A case study in polypharmacology
Ladds, M. J. G. W., Popova, G., Fernández, A. P., Kannan, S., van Leeuwen, I. M. M., Håkansson, M., Walse, B., Tholander, F., Bhatia, R., Verma, C. S., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.012056 · Cited by 21
Machine learning reveals that structural features distinguishing promiscuous and non-promiscuous compounds depend on target combinations
Feldmann, C., & Bajorath, J. (2021) · Scientific Reports · doi:10.1038/s41598-021-87042-z · Cited by 21
Development of new Alzheimer’s disease drug candidates using donepezil as a key model
Eissa, K. I., Kamel, M. M., Mohamed, L. W., & Kassab, A. E. (2023) · Archiv der Pharmazie · doi:10.1002/ardp.202200398 · Cited by 20
ATNC: Versatile Nanobody Chimeras for Autophagic Degradation of Intracellular Unligandable and Undruggable Proteins
He, H., Zhou, C., & Chen, X. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c08843 · Cited by 20
Research progress and perspectives of dual-target inhibitors
Pang, X., Xu, W., Liang, J. Y., Liu, Y., Li, H., & Chen, L. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117453 · Cited by 19
Multi-Target Drugs for Kidney Diseases
Imig, J. D., Merk, D., & Proschak, E. (2021) · Kidney360 · doi:10.34067/kid.0003582021 · Cited by 19
Self-citation
Dual targeted 2-Benzylideneindanone pendant hydroxamic acid group exhibits selective HDAC6 inhibition along with tubulin stabilization effect
Kumar, K., Das, R., Thapa, B., Rakhecha, B., Srivastava, S., Savita, K., Israr, M., Chanda, D., Banerjee, D., Shanker, K., et al. (2023) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2023.117300 · Cited by 19
Recent Progress in Structure-Based Evaluation of Compound Promiscuity
Gilberg, E., & Bajorath, J. (2019) · ACS Omega · doi:10.1021/acsomega.8b03639 · Cited by 19
A triple farnesoid X receptor and peroxisome proliferator-activated receptor α/δ activator reverses hepatic fibrosis in diet-induced NASH in mice
Heitel, P., Faudone, G., Helmstädter, M., Schmidt, J., Kaiser, A., Tjaden, A., Schröder, M., Müller, S., Schierle, S., Pollinger, J. C., et al. (2020) · Communications Chemistry · doi:10.1038/s42004-020-00411-z · Cited by 19
Self-citation
3,17β-Bis-sulfamoyloxy-2-methoxyestra-1,3,5(10)-triene and Nonsteroidal Sulfamate Derivatives Inhibit Carbonic Anhydrase IX: Structure–Activity Optimization for Isoform Selectivity
Andring, J. T., Döhle, W., Tu, C., Potter, B. V. L., & McKENNA, R. V. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01990 · Cited by 19
Dual Farnesoid X Receptor/Soluble Epoxide Hydrolase Modulators Derived from Zafirlukast
Schierle, S., Helmstädter, M., Schmidt, J., Hartmann, M., Horz, M., Kaiser, A., Weizel, L., Heitel, P., Proschak, A., Hernández‐Olmos, V., et al. (2019) · ChemMedChem · doi:10.1002/cmdc.201900576 · Cited by 19
Self-citation
Structure-activity relationship studies of benzothiazole-phenyl analogs as multi-target ligands to alleviate pain without affecting normal behavior
Angelia, J., Weng, X., Solomatov, A., Chin, C., Fernandez, A. M., Hudson, P. K., Morisseau, C. H. P., Hammock, B. D., Kandasamy, R., & Pecic, S. (2022) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2022.106702 · Cited by 18
Intracellular water as a mediator of anticancer drug action
Marques, M. P. M., de Carvalho, A. L. M. B., Mamede, A. P., Rudić, S., Dopplapudi, A., Sakai, V. G., & de Carvalho, L. A. E. B. (2020) · International Reviews in Physical Chemistry · doi:10.1080/0144235x.2020.1700083 · Cited by 18
Novel mutual prodrug of 5-fluorouracil and heme oxygenase-1 inhibitor (5-FU/HO-1 hybrid): design and preliminary in vitro evaluation
Salerno, L., Vanella, L., Sorrenti, V., Consoli, V., Ciaffaglione, V., Fallica, A. N., Canale, V., Zajdel, P., Pignatello, R., & Intagliata, S. (2021) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2021.1928111 · Cited by 18
Macrocyclization as a Source of Desired Polypharmacology. Discovery of Triple PI3K/mTOR/PIM Inhibitors
Martı́nez, S., Álvarez, R. M., Martín, J. I., Garcı́a, A. B., Riesco‐Fagundo, C., Varela, C., Hergueta, A. R., Cantalapiedra, E. G., Albarran, M. I., Gómez‐Casero, E., et al. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00412 · Cited by 18
HDAC/JAK dual target inhibitors of cancer-related targets: The success of nonclearable linked pharmacophore mode
Zhao, L., Liang, Q., He, Y., Liu, M., Tong, R., Jiang, Z., Wang, W., & Shi, J. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.106181 · Cited by 18
Development of novel multipotent compounds modulating endocannabinoid and dopaminergic systems
Grillo, A., Chemi, G., Brogi, S., Brindisi, M., Relitti, N., Fezza, F., Fazio, D., Castelletti, L., Perdonà, E., Wong, A., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111674 · Cited by 18
Novel Multitarget Therapies for Lung Cancer and Respiratory Disease
Yumura, M., Nagano, T., & Nishimura, Y. (2020) · Molecules · doi:10.3390/molecules25173987 · Cited by 17
Discovery of a Novel Template, 7-Substituted 7-Deaza-4′-Thioadenosine Derivatives as Multi-Kinase Inhibitors
Mashelkar, K. K., Byun, W. S., Ko, H., Sung, K., Tripathi, S., An, S., Yum, Y. A., Kwon, J. Y., Kim, M., Kim, G., et al. (2021) · Pharmaceuticals · doi:10.3390/ph14121290 · Cited by 17
Designed multiple ligands for the treatment of type 2 diabetes mellitus and its complications: Discovery of (5-arylidene-4-oxo-2-thioxothiazolidin-3-yl)alkanoic acids active as novel dual-targeted PTP1B/AKR1B1 inhibitors
Maccari, R., Wolber, G., Genovese, M., Sardelli, G., Talagayev, V., Balestri, F., Luti, S., Santi, A., Moschini, R., CORSO, A. D., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115270 · Cited by 17
ProfhEX: AI-based platform for small molecules liability profiling
Lunghini, F., Fava, A., Pisapia, V., Sacco, F. M., Iaconis, D., & Beccari, A. R. (2023) · Journal of Cheminformatics · doi:10.1186/s13321-023-00728-6 · Cited by 17
The Roles of Histone Deacetylases in the Regulation of Ovarian Cancer Metastasis
Xu, L., Yan, X., Wang, J., Zhao, Y., Liu, Q., Fu, J., Shi, X., & Su, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015066 · Cited by 17
The polypharmacology of natural products in drug discovery and development
Choo, M. Z. Y., & Chai, C. L. L. (2023) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2023.10.002 · Cited by 17
Quinolinyl-based multitarget-directed ligands with soluble epoxide hydrolase and fatty acid amide hydrolase inhibitory activities: Synthetic studies and pharmacological evaluations
Angelia, J., Duong, L., Yun, F., Mesic, A., Yuan, C., Carr, D., Gunari, S., Hudson, P. K., Morisseau, C. H. P., Hammock, B. D., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e32262 · Cited by 17
Recent Advances in the Search for Effective Anti-Alzheimer’s Drugs
Ogoś, M., Stary, D., & Bajda, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms26010157 · Cited by 17
Analysis of Biological Screening Compounds with Single- or Multi-Target Activity via Diagnostic Machine Learning
Feldmann, C., Yonchev, D., & Bajorath, J. (2020) · Biomolecules · doi:10.3390/biom10121605 · Cited by 17
Multi or Single-Kinase Inhibitors to Counteract Drug Resistance in Cancer: What is New?
Pecoraro, C., Carbone, D., Cascioferro, S., Parrino, B., & Diana, P. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220729152741 · Cited by 17
Designing Dual Inhibitors of Autotaxin-LPAR GPCR Axis
Banerjee, S., Lee, S.-C., Norman, D. D., & Tigyi, G. (2022) · Molecules · doi:10.3390/molecules27175487 · Cited by 17
Dual-Target Inhibitors Based on PARP1: New Trend in the Development of Anticancer Research
Ge, J., Yin, Y., Li, Y., Deng, Y., & Fu, H. (2022) · Future Medicinal Chemistry · doi:10.4155/fmc-2021-0292 · Cited by 16
Structure-guided identification of novel dual-targeting estrogen receptor α degraders with aromatase inhibitory activity for the treatment of endocrine-resistant breast cancer
Xin, L., Min, J., Hu, H., Li, Y., Du, C., Xie, B., Cheng, Y., Deng, X., Deng, X., Shen, K., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115328 · Cited by 16
A comprehensive review on the progress and challenges of tetrahydroisoquinoline derivatives as a promising therapeutic agent to treat Alzheimer's disease
Thangeswaran, D., Shamsuddin, S., & Balakrishnan, V. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e30788 · Cited by 16
Synthesis, biosimulation and pharmacological evaluation of benzimidazole derivatives with antihypertensive multitarget effect
Gutiérrez-Hernández, A., Estrada-Soto, S. E., Martínez-Conde, C., Gaona-Tovar, E., Medina‐Franco, J. L., Hernández‐Núñez, E., Hidalgo‐Figueroa, S., Castro-Moreno, P., Ibarra-Barajas, M., & Navarrete‐Vázquez, G. (2024) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2024.129879 · Cited by 16
Consecutive Aryne Generation Strategy for the Synthesis of 1,3-Diarylpyrazoles
Kobayashi, T., Hosoya, T., & Yoshida, S. (2020) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.0c00172 · Cited by 16
New Roadmaps for Non-muscle-invasive Bladder Cancer With Unfavorable Prognosis
Pane, K., Mirabelli, P., Coppola, L., Illiano, E., Salvatore, M., & Franzese, M. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00600 · Cited by 16
Pursuing the Complexity of Alzheimer’s Disease: Discovery of Fluoren-9-Amines as Selective Butyrylcholinesterase Inhibitors and N-Methyl-d-Aspartate Receptor Antagonists
Konecny, J., Misiachna, A., Hrabinová, M., Pulkrabkova, L., Benková, M., Prchal, L., Kucera, T., Kobrlová, T., Finger, V., Kolcheva, M., et al. (2020) · Biomolecules · doi:10.3390/biom11010003 · Cited by 16
Differential Therapeutic Effects of FXR Activation, sEH Inhibition, and Dual FXR/sEH Modulation in NASH in Diet-Induced Obese Mice
Helmstädter, M., Schmidt, J., Kaiser, A., Weizel, L., Proschak, E., & Merk, D. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00041 · Cited by 16
Self-citation
Addressing the Target Identification and Accelerating the Repositioning of Anti‐Inflammatory/Anti‐Cancer Organic Compounds by Computational Approaches
Chini, M. G., Lauro, G., & Bifulco, G. (2021) · European Journal of Organic Chemistry · doi:10.1002/ejoc.202100245 · Cited by 16
Recent Advances in Dual BRD4‐Kinase Inhibitors Based on Polypharmacology
Chen, L., Liu, Z., & Li, X. (2022) · ChemMedChem · doi:10.1002/cmdc.202100731 · Cited by 16
Phenotypic Discovery of Thiocarbohydrazone with Anticancer Properties and Catalytic Inhibition of Human DNA Topoisomerase IIα
Cvijetić, I., Herlah, B., Marinković, А., Perdih, A., & Bjelogrlić, S. (2023) · Pharmaceuticals · doi:10.3390/ph16030341 · Cited by 16
Developing kinase inhibitors for malaria: an opportunity or liability?
Mogwera, K. S. P., Chibale, K., & Arendse, L. B. (2023) · Trends in Parasitology · doi:10.1016/j.pt.2023.06.001 · Cited by 16
Systematic Data Analysis and Diagnostic Machine Learning Reveal Differences between Compounds with Single- and Multitarget Activity
Feldmann, C., Yonchev, D., Stumpfe, D., & Bajorath, J. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00901 · Cited by 15
New Phenol Esters for Efficient pH-Controlled Amine Acylation of Peptides, Proteins, and Sepharose Beads in Aqueous Media
Jensen, K. B., Mikkelsen, J. H., Jensen, S., Kidal, S., Friberg, G., Skrydstrup, T., & Gustafsson, M. (2021) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.1c00528 · Cited by 15

Authors: Proschak, E., Stark, H., & Merk, D.
Affiliations: Goethe University Frankfurt (DE)
Heinrich Heine University Düsseldorf (DE)
Corresponding author: Merk, Daniel
ORCID: Proschak, Ewgenij
Stark, Holger
Merk, Daniel
Venue: Journal of Medicinal Chemistry
Publisher: American Chemical Society (ACS)
Published: 2018-07-23
Volume: 62
Issue: 2
Pages: 420-444
ISSN: 0022-2623 (ISSN-L)
1520-4804
DOI: 10.1021/acs.jmedchem.8b00760
OpenAlex: W2884740260
Cited by: 498
References: 251
Citations by year: 2026: 51 · 2025: 56 · 2024: 74 · 2023: 60 · 2022: 86 · 2021: 64 · 2020: 67 · 2019: 39 · 2018: 1
FWCI: 35.15
Type: journal article
Language: en
Open access: closed
Locations: Journal of Medicinal Chemistry (publishedVersion)
PubMed (publishedVersion)
Publikationsdatenbank der Fraunhofer-Gesellschaft (Fraunhofer-Gesellschaft) (submittedVersion)
Fraunhofer-Publica (Fraunhofer-Gesellschaft) (submittedVersion)
Funders: Eidgen?ssische Technische Hochschule Z?rich (16-2 FEL-07)
Deutsche Forschungsgemeinschaft (SFB1039, PR1405/2-2, PR1405/4-1)
European Cooperation in Science and Technology (CA15135)
Topics: Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
Keywords: polypharmacology, multi-target drug design, drug discovery, chemical probes, fragment-based design, crystallography, computer-aided drug design, complex diseases, drug synergy, side effect reduction
MeSH terms: Machine Learning, Animals, Chemistry, Pharmaceutical, Humans, Ligands, Structure-Activity Relationship, Drug Design, Crystallography, X-Ray, Models, Animal, Metabolic Networks and Pathways

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Polypharmacology by Design: A Medicinal Chemist’s Perspective on Multitargeting Compounds

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks